ACR representatives updated members on recent insurance issues…
Search results for: biosimilars
Biologic Spending & Price Trends
Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…
ACR Advocacy: 2019 Year in Review
As a new year begins, Government Affairs Committee chair Blair Solow, MD, takes stock of ACR advocacy wins in 2019 and issues to watch in 2020.
Coding Corner Answers: Rheumatology Word Search
Take the challenge. Answers Biosimilars Methotrexate Time Presenting problem Ultrasound guidance International Classification of Diseases Current Procedural Terminology Trigger points Osteoporosis Osteoarthritis
FDA Approves Amgen’s Infliximab Biosimilar Treatment
(Reuters)—The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab), according to the regulator’s website. The biosimilar, Avsola (infliximab-axxq), has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. The label for the…
The ARP Aids Rheumatology Workforce Expansion Via Online Education
The Advanced Rheumatology Course (ARC) carries the distinction of being the first online educational product of the ACR/ARP. In the early 2000s, members of the College thoughtfully considered action needed to efficiently prepare health professionals looking to enter the rheumatology workforce. A decision was made to create online educational products with the specific target audience…
A Farewell Message from Outgoing Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP
A farewell message from outgoing Government Affairs Committee Chair Angus Worthing urges ACR/ARP members to advocate for the rheumatology profession.
Ellen M. Gravallese, MD, Begins ACR Presidency
As Ellen M. Gravallese, MD, begins the ACR presidency, her goals include workforce expansion, improved access to care and support for members in all areas of practice.
Drug Pricing Bills Move Forward
This week, the U.S. House of Representatives released a long-anticipated plan that contains provisions to reduce U.S. drug prices according to an international price index.
FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)
Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 32
- Next Page »